Online inquiry

IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10027MR)

This product GTTS-WQ10027MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10027MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7969MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ2389MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ3154MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ8860MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ3168MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ3165MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ9940MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ12443MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW